Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Emerging Therapeutic Approaches for Gastrointestinal Malignancies and the Tumour Microenvironment
share announcement

Emerging Therapeutic Approaches for Gastrointestinal Malignancies and the Tumour Microenvironment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 2919

Special Issue Editors

Dr. Khurum Khan

E-Mail Website
Guest Editor
Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, 235 Euston Road, London NW1 2BU, UK
Interests: colorectal cancer; anal cancer; bile duct cancer (cholangiocarcinoma); biliary cancer; cancer of unknown primary; colon cancer; gastrointestinal cancers; medical oncology; small bowel cancer liquid biopsies; tumour heterogeneity; patient-derived organoids; bioinformatics; next generation sequencing
Special Issues, Collections and Topics in MDPI journals
Dr. Kai-Keen Shiu

E-Mail Website
Co-Guest Editor
Department of Gastrointestinal Oncology, University College London Hospital NHS Foundation Trust, London NW1 2PG, UK
Interests: gastrointestinal malignancies; colorectal cancer; immunotherapy
Umair Mahmood

E-Mail
Guest Editor Assistant
University College Hospital Macmillan Cancer Centre, Huntley Street, London WC1E 6AG, UK
Interests: immune checkpoint; gastrointestinal malignancies

Special Issue Information

Dear Colleagues,

In this Special Issue, a collection of studies on the current state of preclinical and clinical investigations shall be assembled. Studies that investigate new promising therapeutic targets, and innovative pathways as well as submissions that evaluate targeted therapies in combination with immuno-therapy and/or conventional systemic therapies, are encouraged. The aim is to summarize the interdisciplinary nature of gastrointestinal treatment, with a focus on targeted therapeutic strategies.

Potential topics include, but are not limited to, the following:

  • Current and new therapeutic targets in gastrointestinal cancer subtypes;
  • Diagnosis and selection of patients with gastrointestinal cancers for targeted therapy;
  • Personalized medicine initiatives for gastrointestinal malignancies;
  • Role of multi-modality treatment in the setting of neoadjuvant therapy;
  • Implications of the combination of targeted therapeutics with immune-therapies and/or conventional chemotherapies.

Dr. Khurum Khan
Dr. Kai-Keen Shiu
Guest Editors

Umair Mahmood
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal malignancies
  • treatment
  • cancer therapy
  • tumor microenvironment
  • neoadjuvant therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

21 pages, 3577 KiB  
Article
Comprehensive Examination of Cholangiocarcinoma Patients Treated with Novel Targeted Therapies after Extended Molecular Profiling on Liquid Biopsies
by Umair Mahmood, Elisya Muhamad Faizul, Sarah Howlett, Zahir Amin, Daniel Hochhauser, Kai-Keen Shiu, John Bridgewater and Khurum Khan
Cancers 2024, 16(4), 697; https://doi.org/10.3390/cancers16040697 - 06 Feb 2024
Viewed by 1557
Abstract
Background: Cholangiocarcinoma (CCA) is associated with poor outcomes and limited treatment options, leading to increased use of targeted therapies for its management. Here, we performed one of the largest single-centre reviews evaluating outcomes following personalised targeted agents in CCA patients. Methods: All consecutive [...] Read more.
Background: Cholangiocarcinoma (CCA) is associated with poor outcomes and limited treatment options, leading to increased use of targeted therapies for its management. Here, we performed one of the largest single-centre reviews evaluating outcomes following personalised targeted agents in CCA patients. Methods: All consecutive CCA patients receiving systemic therapy between January 2010 and April 2023 at UCLH were included. The primary objective of this study was to evaluate treatment response, survival outcomes and predictors of clinical benefit in CCA patients treated with molecularly guided therapies. Patient demographic factors, disease characteristics and survival outcomes were evaluated using the Kaplan–Meier method and Cox proportional-hazards models. Results: Of the 227 consecutive CCA patients, 162 (71%) had molecular profiling, of whom 56 (35%) were eligible and 55 received molecular-targeted treatment. CCA histological classifications comprised intrahepatic (N = 32), extrahepatic (N = 11), hilar (N = 4) and unknown (N = 9) subtypes. Most patients received targeted agents based on genomic profiling in a second treatment line setting (N = 34). Frequently observed genomic alterations occurred in the FGFR2 (N = 21), IDH1 (N = 7) and BRCA2 (N = 6) genes. Median progression-free survival (PFS) following first-, second- and third-line systemic therapy and overall survival (OS) were 8.44 (95% CI, 7.49–12.78), 5.65 (95% CI, 3.71–7.13), 5.55 (2.79–12.58) and 29.01 (24.21–42.91) months, respectively. CCA subtype and FGFR/BRCA molecular aberration status were not associated with PFS or OS. However, a prior CCA-related surgical history was predictive of OS (p = 0.02). Stratification by best overall response to second-line targeted agents demonstrated an association with PFS (p = 0.002) and OS (p = 0.02). Duration of treatment with second-line targeted therapy was associated with OS (p < 0.001). Conclusions: Patients receiving targeted therapeutics achieved promising outcomes, especially those attaining a favourable treatment response and those receiving targeted agents for longer periods. Liquid biopsies can reliably provide information on extended molecular profiling to aid patient selection for personalised therapies. Full article
(This article belongs to the Special Issue Emerging Therapeutic Approaches for Gastrointestinal Malignancies and the Tumour Microenvironment)
►▼ Show Figures

Figure 1

12 pages, 874 KiB  
Article
Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer
by Irene Assaf, Danai Fimereli, Geraldine Anthoine, Roberta Fazio, Valentina Daprà, Alessandro Audisio, Alina Bardiaux, Tugba Akin Telli, Michele Vanhooren, Rita Saude-Conde, Giacomo Bregni, Alain Hendlisz and Francesco Sclafani
Cancers 2023, 15(24), 5823; https://doi.org/10.3390/cancers15245823 - 13 Dec 2023
Viewed by 804
Abstract
Circulating cytokines could be optimal biomarkers for prognostication and management decisions in colorectal cancer (CRC). Chemorefractory CRC patients with available plasma samples were included in this study. In the discovery cohort (n = 85), 182 circulating cytokines were tested with a semi-quantitative [...] Read more.
Circulating cytokines could be optimal biomarkers for prognostication and management decisions in colorectal cancer (CRC). Chemorefractory CRC patients with available plasma samples were included in this study. In the discovery cohort (n = 85), 182 circulating cytokines were tested with a semi-quantitative multiplex assay, and prognostic cytokines were analyzed in the validation cohort (n = 111) by ELISA. Overall survival (OS) was the primary outcome measure, with the false discovery rate (FDR) method (significance level of <0.01) being used to correct for multiple comparisons. Four cytokines were associated with OS in the discovery cohort: insulin-like growth factor-binding protein 1 (IGFBP-1) (HR 2.1 [95%CI: 1.58–2.79], FDR < 0.001), insulin-like growth factor-binding protein 2 (IGFBP-2) (HR 1.65 [95%CI: 1.28–2.13], FDR = 0.006), serum amyloid A (SAA) (HR 1.84 [95%CI: 1.39–2.43], FDR < 0.001), and angiotensin II (HR 1.65 [95%CI: 1.29–2.1], FDR = 0.006). Of these, IGFBP-1 (HR 2.70 [95%CI: 1.56–4.76], FDR = 0.007) and IGFBP-2 (HR 3.33 [95%CI: 1.64–6.67], FDR = 0.008) were confirmed to be independently associated with OS in the validation cohort. Patients with high concentrations of IGFBP-1 and/or IGFBP-2 had a median OS of 3.0 months as compared with 6.9 months for those with low concentrations of both cytokines (HR 2.44 [95%CI: 1.52–4.0], FDR = 0.002) Validation of circulating IGFBP-1 and IGFBP-2 as independent prognostic biomarkers for chemorefractory CRC in larger, independent series is warranted. Full article
(This article belongs to the Special Issue Emerging Therapeutic Approaches for Gastrointestinal Malignancies and the Tumour Microenvironment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop